Otolaryngologists must have a high degree of clinical suspicion for midline nasal masses in children. Benign tumors-including dermoid cysts, gliomas, and vascular malformations, as well as neoplasms of the head and neck-need to be considered. This report describes the histopathology of a rare pediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), a myxoid malignant fibrous histiocytoma (MMFH), presenting in a young child as a subcutaneous nasal mass.
Introduction
Otolaryngologists must have a high degree of clinical suspicion for midline nasal masses in children. Benign tumors-including dermoid cysts, gliomas, and vascular malformations, as well as neoplasms of the head and neck-need to be considered. This report describes the histopathology of a rare pediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), a myxoid malignant fibrous histiocytoma (MMFH), presenting in a young child as a subcutaneous nasal mass.
This case illustrates the unique clinical presentation of the MMFH and delineates common pitfalls that can be associated with the diagnosis of this lesion. A review of the treatment options for MMFHs reinforces the need for tumor-specific protocols in order to successfully treat pediatric NRSTSs.
Case report
A healthy 5-year-old girl was referred to the Geisinger Medical Center's Department of Otolaryngology with a 5-month history of a nasal lesion that reportedly appeared after minor trauma to the nose. On examination, a nontender, firm subcutaneous mass of the nasal dorsum with overlying telangectasias was found (figure 1). No cervical masses or pathologic adenopathy was palpated. Magnetic resonance imaging (MRI) of the head and neck revealed an enhancing mass in the nasal subcutaneous tissues, favoring a diagnosis of a traumatic arterial venous (AV) malformation (figure 2). Fine-needle aspiration (FNA) of the lesion was not performed.
Despite the clinical and radiologic diagnosis of an AV malformation, the lesion increased in size within weeks of the initial presentation, which raised concerns regarding the possibility of a malignant process. After a lengthy discussion with the child's parents, we elected to pursue excisional biopsy for diagnosis and treatment. The child's family was made aware of the potential for delayed nasal reconstruction, dependent on the resultant deformity and pathologic diagnosis.
Intraoperatively, a midline dorsal nasal incision was created over the soft-tissue mass. Immediately after we passed through the subcutaneous layer of the skin, we encountered a solid lesion with a mucoid component ( figure 3 ). The lesion did not have a definable capsule and was adherent to the overlying skin and underlying periosteum of the nasal bones.
The mass was resected, with care taken not to disrupt the underlying periosteum. All gross evidence of the tumor was removed. The nasal bones remained intact, without evidence of intranasal extension by gross exam and nasal endoscopy. The excised lesion measured approximately 3.5 × 3.0 × 1.6 cm (figure 4, A). Intraoperative frozen section pathology reported inflammatory cells, mucus, and fibroblasts, without evidence of malignancy. A layered wound closure was performed. The specimen was reviewed by several pathologists across the country, experts in pediatric oncology and/ or sarcomas. The final pathologic report described the lesion as having cytologic atypia, a brisk mitotic rate, and CD68 positivity, consistent with the American Joint Committee on Cancer's MMFH grade I-II/III ( figure  4, B) . 1 The patient was referred to pediatric oncology for further evaluation. Oncologic workup, including a full-body bone scan and computed tomography of the thorax, was negative for persistent or metastatic disease. The multidisciplinary tumor board recommended no further treatment.
The child was to be followed by the departments of Otolaryngology and Oncology, with repeat imaging every 6 months. A follow-up MRI performed approximately 8 months after surgery showed no residual softtissue enhancement over the nasal bones or within the surrounding soft tissue. The patient was subsequently lost to follow-up.
Discussion
Malignant fibrous histiocytoma belongs to a large and diverse group of soft-tissue neoplasms called fibrohistiocytic tumors. The five subtypes of malignant fibrous histiocytoma include: pleomorphic, angiomatoid, myxoid, giant cell, and inflammatory. 2 Fibrosarcomas are the most common sarcomatous neoplasms after rhabdomyoscarcoma, accounting for 11% of all softtissue sarcomas in childhood. 3 On contrast-enhanced imaging, an MMFH can present as an enhancing lesion of the head or neck which, as illustrated by this case, can raise suspicion for midline congenital lesions or vascular malformations of the face.
The Pediatric Oncology Group developed a grading system based on the tumor's histologic features, mitotic activity, and amount of necrosis. 4 Lesions evaluated by FNA can be misdiagnosed because of the appearance of cellular features typical of ordinary fibroblasts. 2 The Intergroup Rhabdomyosarcoma Study Group (IRS) surgicopathologic staging system includes 4 :
• group I: completely resected tumors, • group II: macroscopically resected tumors with microscopic residual disease at the primary site,
• group III: macroscopically residual disease, and
• group IV: distant metastases. 4 Three of these patients developed the malignancy after irradiation for Hodgkin lymphoma. The most common primary tumor site was the extremities, followed by the head and neck.
Prognostic factors in pediatric fibrohistiocytic tumors are related to tumor histology and complete surgical resection. A common pitfall is subtotal resection, which highlights the importance of accurate intraoperative frozen section cytopathology and definitive permanent section diagnosis. There is a positive correlation with survival and event-free survival (EFS) for patients who undergo wide local excision compared to partial resection or excision. 4 IRS clinical group (I, II, III), tumor invasiveness, and tumor size are also considered predictors of overall survival and EFS in pediatric patients with MMFH. 4 Adjuvant radiotherapy may reduce the incidence of local recurrence in children with confirmed or assumed microscopic residual disease after surgery. It may be argued that in cases of residual tumor in the head and neck region in which further resection may negatively impact aesthetic and functional outcomes, this option may be a reasonable one. Chemotherapy may play a role in metastatic or unresectable MMFH but, in general, most NRSTSs do not respond favorably to this modality.
NRSTSs of childhood are exceedingly rare tumors of the pediatric head and neck. To the best of our knowledge, from our review of the contemporary literature, this is the first reported case of an MMFH presenting as a midline nasal mass in a child. The case illustrates that the common diagnostic tools, including contrastenhanced imaging, can lead to misdiagnosis of these childhood tumors. In summary, in children with MMFH, wide local excision is recommended regardless of the tumor grade. Clinical group (I, II, III), tumor invasiveness, and tumor size are predictors of survival and EFS. Adjuvant radiation therapy may have a role for locoregional control of select lesions. Chemotherapy generally has a very limited place in advanced NRSTSs. Pooled data on therapy outcomes and treatment responses across the nation's major children's centers is necessary for developing novel therapies and effective protocols for treatment of this rare pediatric sarcoma.
